Semin Thromb Hemost 2025; 51(01): 091-097
DOI: 10.1055/s-0044-1800834
Review Article

Hereditary Hemorrhagic Telangiectasia: On the Brink of a New Treatment Era?

Antonio Cerrone
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Elisabetta Buscarini
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Roberto Berté
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Saverio Alicante
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Stefania Bertolazzi
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Olivia Moreschi
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Paola Griffanti
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
,
Guido Manfredi
1   Gastroenterology Department, HHT European Reference Center, ASST Ospedale Maggiore Crema, Crema, Italy
› Author Affiliations
Preview

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder with highly variable penetrance, affecting up to 1 in 5,000 individuals. It is characterized by the presence of abnormal blood vessels that can lead to excessive bleeding—most frequently recurrent nosebleeds (epistaxis), skin and mucosal telangiectasias (small, dilated blood vessels), as well as arteriovenous malformations (AVMs) that can form in various organs, particularly the lungs, liver, and brain. HHT is caused by loss-of-function mutations in the BMP9–10/ENG/ALK1/SMAD4 signaling pathway, an important mediator of vascular quiescence. HHT possesses significant challenges for affected individuals, as the complications can range from mild to life-threatening events, depending on the severity and location of the vascular abnormalities. Despite this bleeding disorder being not uncommon, nowadays no specific treatment is as yet available for HHT and most current therapies include repurposed drugs. The aim of this review was to show therapeutic advances on the basis of recent promising clinical trials for HHT.



Publication History

Article published online:
18 December 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA